NIHR research program aims to increase safety, well-being of victims of DVA

Researchers at the University of Bristol have received more than £2.5 million from the National Institute for Health Research (c) to carry out research that aims to increase the safety and well-being of victims of domestic violence and abuse (DVA).

Reaching Everyone Programme of Research On Violence In diverse Domestic Environments (REPROVIDE), is a six-year programme will investigate ways of improving how healthcare professionals respond to all family members experiencing or perpetrating DVA and will study the effect of a perpetrator group.

REPROVIDE will examine the value of training general practice staff about the needs of children exposed to DVA, and of men experiencing or perpetrating DVA, and linking them to specialist services. It will also examine the value of a group programme for men who perpetrate DVA to help them stop being abusive.

Professor Gene Feder, GP and Professor of Primary Care at the University of Bristol's Centre for Academic Primary Care, is leading the research. He said: "This is probably the most challenging DVA and health research programme to date. Through the IRIS general practice training and support programme, now commissioned in over 30 areas of England and Wales, we have already shown that with training, general practice staff can respond appropriately to women experiencing DVA. We want to extend this model to train general practice staff on how to deal with male victims and perpetrators, and integrate the responses to men, women and children."

Dr Jayne Bailey, programme manager, said: "The second part of our research will investigate the effectiveness of programmes for men who perpetrate DVA. While perpetrator groups exists, there is no UK-based randomised control trial evidence about their effectiveness. . We will investigate which is the most promising programme, and this will be adapted and tested first in a small group of men who have perpetrated DVA and their partners or ex-partners. If this looks promising, we will test it in a large experimental study based in primary care."